speb/financial-data huggingface dataset:
Stock screener scorecard for 5975.T (annual, report date 2026-03-31)
Altman Z-score: 2.7586312341545667 (Grey Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 10.923312441326441%
Earnings yield: 0.15810021851557118%
Return on net tangible assets: 5.894599439868475%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 9.544555668632853%
Free cash flow margin: 1.3692699602708447%
Revenue growth: -5.07913663754769%
Rule of 40 score: -3.7098666772768456
Market cap: 130538627072 (Large Cap ($10B-$200B))
P/E ratio: 0.039512845823240356
Debt to equity: 0.1838
Free cash flow (dilution adjusted): 32451201.2012012
Operating income: 175437937.93793795
Net income: 117536286.28628628
Long score: 8 | Short score: 1
Recommendation: Long
Stock screener scorecard for AARTIIND.NS (annual, report date 2026-03-31)
Altman Z-score: 2.130194651945937 (Grey Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 9.049592300494586%
Earnings yield: 0.03317235983554177%
Return on net tangible assets: 15.663918610770041%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 8.195133761045877%
Free cash flow margin: 9.304851556842868%
Revenue growth: 3.3359826881603327%
Rule of 40 score: 12.640834245003202
Market cap: 173310803968 (Large Cap ($10B-$200B))
P/E ratio: 0.3642107638085211
Debt to equity: 0.8339
Free cash flow (dilution adjusted): 81708350.99618483
Operating income: 71746502.75540483
Net income: 44404408.64773209
Long score: 5 | Short score: 1
Recommendation: Neutral
Stock screener scorecard for AARTIIND.NS (quarterly, report date 2026-03-31)
Altman Z-score: 1.558550167398227 (Distress Zone)
Piotroski F-score: 3 (Weak)
Return on capital: 2.887314530143029%
Earnings yield: 0.010583795752550994%
Return on net tangible assets: 4.490440273636205%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 2.6146955574385666%
Revenue growth: -9.502109666831378%
Rule of 40 score: -9.502109666831378
Market cap: 173310803968 (Large Cap ($10B-$200B))
P/E ratio: 0.3642107638085211
Debt to equity: 0.8339
Operating income: 22891055.532005087
Net income: 14518863.925392115
Long score: 1 | Short score: 6
Recommendation: Neutral
Stock screener scorecard for ANET (quarterly, report date 2026-03-31)
Altman Z-score: 17.733588393248088 (Safe Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 9.453820966938572%
Earnings yield: 0.5600393901937617%
Return on net tangible assets: 7.749169759718695%
Capitalized R&D asset: 684708000
ROCI (R&D adjusted): 7.364079463452968%
Rosenberg metric: 0.3243398392652124
Free cash flow margin: 56.0391288298265%
Revenue growth: 8.891389983117614%
Rule of 40 score: 64.93051881294411
Market cap: 219082899456 (Mega Cap (>= $200B))
P/E ratio: 42.192439862542955
Debt to equity: 0
Free cash flow (dilution adjusted): 1518100000
Operating income: 1157800000
Net income: 1022900000
Long score: 8 | Short score: 3
Recommendation: Neutral
Stock screener scorecard for ATS.TO (annual, report date 2026-03-31)
Altman Z-score: 2.118544257458942 (Grey Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 20.641836582824826%
Earnings yield: 3.3345511705419746%
Return on net tangible assets: -62.23526738838092%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 6.720521777158077%
Free cash flow margin: 12.329579014925333%
Revenue growth: 20.73179204259446%
Rule of 40 score: 33.06137105751979
Market cap: 3614485760 (Mid Cap ($2B-$10B))
P/E ratio: 38.64196314181532
Debt to equity: 0.8187000000000001
Free cash flow (dilution adjusted): 263705035.97122303
Operating income: 159646043.16546765
Net income: 51606474.820143886
Long score: 8 | Short score: 3
Recommendation: Long
Stock screener scorecard for ATS.TO (quarterly, report date 2026-03-31)
Altman Z-score: 1.4545974875057393 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 2.1585243339782707%
Earnings yield: 0.34869522465357944%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 0.7027673983765937%
Free cash flow margin: 16.388771026217267%
Revenue growth: -3.19458195172269%
Rule of 40 score: 13.194189074494577
Market cap: 3614485760 (Mid Cap ($2B-$10B))
P/E ratio: 38.64196314181532
Debt to equity: 0.8187000000000001
Free cash flow (dilution adjusted): 88087050.35971223
Operating income: 16694244.604316548
Net income: -11586330.935251798
Long score: 3 | Short score: 3
Recommendation: Neutral
Stock screener scorecard for CIPLA.NS (annual, report date 2026-03-31)
Altman Z-score: 10.89050683710283 (Safe Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 19.29240120225145%
Earnings yield: 0.0490794069975929%
Return on net tangible assets: 12.2802825812276%
Capitalized R&D asset: 101724505.06232703
ROCI (R&D adjusted): 13.424676044834413%
Rosenberg metric: -4.615977385720074
Free cash flow margin: 2.892858573403499%
Revenue growth: -7.456039789156963%
Rule of 40 score: -4.563181215753465
Market cap: 1123085189120 (Mega Cap (>= $200B))
P/E ratio: 0.26630925134914546
Debt to equity: 0.0178
Free cash flow (dilution adjusted): 84957609.15642221
Operating income: 513514200.9325986
Net income: 411109580.3306486
Long score: 8 | Short score: 1
Recommendation: Long
Stock screener scorecard for CIS.DE (quarterly, report date 2026-04-30)
Altman Z-score: 3.2749480826688653 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 344.2608695652174%
Earnings yield: 0.9700112512908022%
Return on net tangible assets: -19.670696351403098%
Capitalized R&D asset: 4746850000
ROCI (R&D adjusted): 4.362078201895241%
Rosenberg metric: 0.045859872611464965
Free cash flow margin: 15.333627927529827%
Revenue growth: 3.2054205485699394%
Rule of 40 score: 18.539048476099765
Market cap: 391778598912 (Mega Cap (>= $200B))
P/E ratio: 34.01273322132815
Debt to equity: 0.6754000000000001
Free cash flow (dilution adjusted): 2429000000
Operating income: 3959000000
Net income: 3373000000
Long score: 8 | Short score: 4
Recommendation: Neutral
Stock screener scorecard for DBX (quarterly, report date 2026-03-31)
Altman Z-score: -0.4975935403098085 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 19.378714814399462%
Earnings yield: 1.8132507529691644%
Return on net tangible assets: -6.1212218391726125%
Capitalized R&D asset: 369582000
ROCI (R&D adjusted): 7.755066938393665%
Rosenberg metric: -0.014446227929373997
Free cash flow margin: 21.000794281175537%
Revenue growth: -1.0531279471864192%
Rule of 40 score: 19.94766633398912
Market cap: 6810046464 (Mid Cap ($2B-$10B))
P/E ratio: 12.415300546448087
Debt to equity: -1.9926430382263758
Free cash flow (dilution adjusted): 132200000
Operating income: 172800000
Net income: 114500000
Long score: 5 | Short score: 8
Recommendation: Neutral
Stock screener scorecard for GMED (quarterly, report date 2026-03-31)
Altman Z-score: 9.814318179685754 (Safe Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 6.9389877835053975%
Earnings yield: 1.641238002297599%
Return on net tangible assets: 6.006956024213929%
Capitalized R&D asset: 73301320
ROCI (R&D adjusted): 3.2119489747308%
Rosenberg metric: -1.0929679506678096
Free cash flow margin: 19.75800614328542%
Revenue growth: -8.054742140800078%
Rule of 40 score: 11.703264002485342
Market cap: 10383106048 (Large Cap ($10B-$200B))
P/E ratio: 20.130841121495326
Debt to equity: 0.0245
Free cash flow (dilution adjusted): 150132000
Operating income: 161977000
Net income: 124302000
Long score: 8 | Short score: 0
Recommendation: Long
Stock screener scorecard for GMRAIRPORT.NS (annual, report date 2026-03-31)
Altman Z-score: 1.6632211787568818 (Distress Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 13.700088620515535%
Earnings yield: 0.029381082603978065%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 9.928599588451338%
Free cash flow margin: 10.500350837857532%
Revenue growth: 28.89403916723385%
Rule of 40 score: 39.39439000509138
Market cap: 1131077566464 (Mega Cap (>= $200B))
P/E ratio: 6.8782768191926245
Debt to equity: -27.939167425137324
Free cash flow (dilution adjusted): 164776388.30012718
Operating income: 442512717.25307333
Net income: 50062526.49427724
Long score: 6 | Short score: 4
Recommendation: Neutral
Stock screener scorecard for GMRAIRPORT.NS (quarterly, report date 2026-03-31)
Altman Z-score: 1.2752933929943766 (Distress Zone)
Piotroski F-score: 2 (Weak)
Return on capital: 3.3844112543133194%
Earnings yield: 0.007258176890907645%
Return on net tangible assets: -11.331971387826243%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 2.452718746388725%
Revenue growth: -6.1951427108605275%
Rule of 40 score: -6.1951427108605275
Market cap: 1131077566464 (Mega Cap (>= $200B))
P/E ratio: 6.8782768191926245
Debt to equity: -27.939167425137324
Operating income: 109316447.64730819
Net income: 42442772.36116999
Long score: 1 | Short score: 8
Recommendation: Short
Stock screener scorecard for HBSA3.SA (quarterly, report date 2026-03-31)
Altman Z-score: 0.7904537459657757 (Distress Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 1.9942514952711445%
Earnings yield: 0.25475892701067593%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 1.7218434448055904%
Free cash flow margin: -14.693494293101628%
Revenue growth: -4.602818256810107%
Rule of 40 score: -19.296312549911733
Market cap: 4693320192 (Mid Cap ($2B-$10B))
P/E ratio: 77.56653992395438
Debt to equity: 1.8534
Free cash flow (dilution adjusted): -12435361.216730038
Operating income: 18844296.577946767
Net income: -6496577.946768061
Long score: 0 | Short score: 7
Recommendation: Neutral
Stock screener scorecard for ITCHOTELS.NS (annual, report date 2026-03-31)
Altman Z-score: 11.594559625460628 (Safe Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 10.112536015237053%
Earnings yield: 0.03536838325149044%
Return on net tangible assets: 7.140890916723441%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 8.632662115319926%
Free cash flow margin: 17.012401682111985%
Revenue growth: 5.648922978422368%
Rule of 40 score: 22.661324660534355
Market cap: 319466045440 (Mega Cap (>= $200B))
P/E ratio: 0.36865716955699773
Debt to equity: 0.0063
Free cash flow (dilution adjusted): 74084357.7787198
Operating income: 112592200.08478169
Net income: 87034760.49173379
Long score: 9 | Short score: 0
Recommendation: Long
Stock screener scorecard for JBCHEPHARM.NS (annual, report date 2026-03-31)
Altman Z-score: 31.67210074236818 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 30.068676093878356%
Earnings yield: 0.02548699903691841%
Return on net tangible assets: 28.21918495854781%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 20.579789735358226%
Free cash flow margin: 13.486123644922419%
Revenue growth: -4.320389373610187%
Rule of 40 score: 9.165734271312232
Market cap: 387925901312 (Mega Cap (>= $200B))
P/E ratio: 0.4867385418296476
Debt to equity: 0.0009
Free cash flow (dilution adjusted): 58257831.708351
Operating income: 95472329.3768546
Net income: 75188077.57524374
Long score: 11 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for JBCHEPHARM.NS (quarterly, report date 2026-03-31)
Altman Z-score: 30.53574210151179 (Safe Zone)
Piotroski F-score: 3 (Weak)
Return on capital: 5.043950323631227%
Earnings yield: 0.004275384677372801%
Return on net tangible assets: 5.269682567243977%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 3.452211755909531%
Revenue growth: -19.20457074915218%
Rule of 40 score: -19.20457074915218
Market cap: 387925901312 (Mega Cap (>= $200B))
P/E ratio: 0.4867385418296476
Debt to equity: 0.0009
Operating income: 16015260.703688003
Net income: 10742899.533700721
Long score: 4 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for MLX.AX (annual, report date 2025-12-31)
Altman Z-score: 11.219063327938683 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 24.609123016384984%
Earnings yield: 8.198180876478874%
Return on net tangible assets: 14.852976247481378%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 21.536792336326585%
Free cash flow margin: 31.920813757241252%
Revenue growth: 40.67192270850122%
Rule of 40 score: 72.59273646574248
Market cap: 1289699712 (Small Cap ($300M-$2B))
P/E ratio: 6.263982102908278
Debt to equity: 0.0062
Free cash flow (dilution adjusted): 61056375.838926174
Operating income: 81930872.48322147
Net income: 70204697.98657718
Long score: 12 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for NVEC (annual, report date 2026-03-31)
Altman Z-score: 153.64730210019655 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 44.771094310719924%
Earnings yield: 2.9065592724677116%
Return on net tangible assets: 23.124808335261392%
Capitalized R&D asset: 6497653.95
ROCI (R&D adjusted): 24.195563900887247%
Rosenberg metric: -0.2495242082354679
Free cash flow margin: 54.593737365282536%
Revenue growth: 1.764364826884523%
Rule of 40 score: 56.35810219216706
Market cap: 535474368 (Small Cap ($300M-$2B))
P/E ratio: 20.56190476190476
Debt to equity: 0.015600000000000001
Free cash flow (dilution adjusted): 14375196
Operating income: 15920491
Net income: 15199195
Long score: 14 | Short score: 2
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for NVEC (quarterly, report date 2026-06-30)
Altman Z-score: 148.0974747619028 (Safe Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 18.884331353526665%
Earnings yield: 1.3265032465411841%
Return on net tangible assets: 10.98984790679258%
Capitalized R&D asset: 1725827.04
ROCI (R&D adjusted): 11.829947996898458%
Rosenberg metric: 3.9146469708777394
Free cash flow margin: 47.44796950024819%
Revenue growth: 44.1454819364462%
Rule of 40 score: 91.5934514366944
Market cap: 568609024 (Small Cap ($300M-$2B))
P/E ratio: 28.104838709677416
Debt to equity: 0.0152
Free cash flow (dilution adjusted): 5235436
Operating income: 7265836
Net income: 6394191
Long score: 14 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for OSIS (quarterly, report date 2026-03-31)
Altman Z-score: 2.59771065285414 (Grey Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 4.519429161589647%
Earnings yield: 1.3900875668927497%
Return on net tangible assets: 14.460163903744135%
Capitalized R&D asset: 39434440
ROCI (R&D adjusted): 2.855466916773732%
Rosenberg metric: -0.06604585252290096
Free cash flow margin: -0.9065717071965333%
Revenue growth: -2.329670708555199%
Rule of 40 score: -3.2362424157517324
Market cap: 3571842304 (Mid Cap ($2B-$10B))
P/E ratio: 30.343999999999998
Debt to equity: 1.1687
Free cash flow (dilution adjusted): -4109000
Operating income: 59382000
Net income: 40216000
Long score: 4 | Short score: 8
Recommendation: Neutral
Stock screener scorecard for PICCADIL.NS (quarterly, report date 2026-03-31)
Altman Z-score: 6.497358562719069 (Safe Zone)
Piotroski F-score: 2 (Weak)
Return on capital: 6.5612523161678995%
Earnings yield: 0.009260202905285017%
Return on net tangible assets: 5.659023983284939%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 6.049693257299895%
Revenue growth: 15.65439041934006%
Rule of 40 score: 15.65439041934006
Market cap: 72665374720 (Large Cap ($10B-$200B))
P/E ratio: 0.38358608914500675
Debt to equity: 0.5889
Operating income: 6957799.915218313
Net income: 4793164.476473082
Long score: 3 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for PICCADIL.NS (annual, report date 2026-03-31)
Altman Z-score: 7.214357164650597 (Safe Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 21.000938309709362%
Earnings yield: 0.029639608504320413%
Return on net tangible assets: -3.6098175014264204%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 19.363564875588096%
Free cash flow margin: -7.838847411098623%
Revenue growth: 15.45647686914037%
Rule of 40 score: 7.617629458041748
Market cap: 72665374720 (Large Cap ($10B-$200B))
P/E ratio: 0.38358608914500675
Debt to equity: 0.5889
Free cash flow (dilution adjusted): -8582217.041119117
Operating income: 22270188.63925392
Net income: 14561350.148367953
Long score: 5 | Short score: 5
Recommendation: Neutral
Stock screener scorecard for PRS.OL (quarterly, report date 2026-03-31)
Altman Z-score: 2.7101309853682607 (Grey Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 1.3904982618771726%
Earnings yield: 0.03535955959308633%
Return on net tangible assets: -13.900709219858154%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 1.3799448022079115%
Free cash flow margin: 56.34095634095634%
Revenue growth: -29.92678192726898%
Rule of 40 score: 26.41417441368736
Market cap: 1533540096 (Small Cap ($300M-$2B))
P/E ratio: 0.02155647521707615
Debt to equity: 2.1136
Free cash flow (dilution adjusted): 2785200.4110996914
Operating income: 616649.5375128469
Net income: -102774.9229188078
Long score: 3 | Short score: 7
Recommendation: Neutral
Stock screener scorecard for RH (quarterly, report date 2026-04-30)
Altman Z-score: 0.5074799538677099 (Distress Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 1.023531693972901%
Earnings yield: 0.4714266094838988%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 0.8667314633417873%
Free cash flow margin: 0.170180226107296%
Revenue growth: -5.019445232328099%
Rule of 40 score: -4.849265006220803
Market cap: 3302814464 (Mid Cap ($2B-$10B))
P/E ratio: 25.474903474903478
Debt to equity: 70.60079999999999
Free cash flow (dilution adjusted): 1362000
Operating income: 34243000
Net income: -13697000
Long score: 2 | Short score: 6
Recommendation: Neutral
Stock screener scorecard for RNO.PA (annual, report date 2025-12-31)
Altman Z-score: 0.518919540313804 (Distress Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 21.668058704211898%
Earnings yield: 7.296058405280004%
Return on net tangible assets: -53.64048539805307%
Capitalized R&D asset: 4928489950.980392
ROCI (R&D adjusted): 10.166827851542733%
Rosenberg metric: 0.32744580681876956
Free cash flow margin: -1.2171541037947586%
Revenue growth: 16.335517561698182%
Rule of 40 score: 15.118363457903424
Market cap: 7480779264 (Mid Cap ($2B-$10B))
Debt to equity: 3.1551
Free cash flow (dilution adjusted): -829411764.7058824
Operating income: 4272941176.470588
Net income: -12700000000
Long score: 3 | Short score: 10
Recommendation: Strong Short (Melting Ice Cube)
Stock screener scorecard for SGIL.NS (annual, report date 2026-03-31)
Altman Z-score: 2.547681474591892 (Grey Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 7.264222681614105%
Earnings yield: 0.017418000580900404%
Return on net tangible assets: -105.49000121913825%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 7.1548996780203575%
Free cash flow margin: -33.406274655146966%
Revenue growth: -7.952886032654513%
Rule of 40 score: -41.35916068780148
Market cap: 9263520768 (Mid Cap ($2B-$10B))
P/E ratio: 1.6909522723764396
Debt to equity: 2.2540999999999998
Free cash flow (dilution adjusted): -12761805.849936415
Operating income: 2028815.1759220008
Net income: 493482.40779991524
Long score: 1 | Short score: 8
Recommendation: Short
Stock screener scorecard for SGIL.NS (quarterly, report date 2026-03-31)
Altman Z-score: 1.921477121431726 (Grey Zone)
Piotroski F-score: 3 (Weak)
Return on capital: 0.9850616688067853%
Earnings yield: 0.002361960180946278%
Return on net tangible assets: 7.610101114587914%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 0.970236971784268%
Revenue growth: 23.332786948395093%
Rule of 40 score: 23.332786948395093
Market cap: 9263520768 (Mid Cap ($2B-$10B))
P/E ratio: 1.6909522723764396
Debt to equity: 2.2540999999999998
Operating income: 275116.5748198389
Net income: 43175.07418397626
Long score: 1 | Short score: 5
Recommendation: Neutral
Stock screener scorecard for SHA.AX (annual, report date 2025-06-30)
Altman Z-score: 5.380195138247865 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 40.04400243265479%
Earnings yield: 3.161780513796292%
Return on net tangible assets: 94.51105782041033%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 30.85478802580075%
Free cash flow margin: 5.4049005951627205%
Revenue growth: 11.708554545482183%
Rule of 40 score: 17.113455140644902
Market cap: 562032768 (Small Cap ($300M-$2B))
P/E ratio: 9.215686274509805
Debt to equity: 0.9706999999999999
Free cash flow (dilution adjusted): 33476470.588235293
Operating income: 14632026.143790849
Net income: 13805882.352941176
Long score: 10 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for SWKS (quarterly, report date 2026-03-31)
Altman Z-score: 3.9528879120753997 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 1.6667190792163273%
Earnings yield: 0.6006520936615877%
Return on net tangible assets: 2.0995361489903392%
Capitalized R&D asset: 422301000
ROCI (R&D adjusted): 0.748769397732833%
Rosenberg metric: -0.20599803343166176
Free cash flow margin: -10.119741443255272%
Revenue growth: -8.85648058721267%
Rule of 40 score: -18.976222030467945
Market cap: 9055943680 (Mid Cap ($2B-$10B))
P/E ratio: 22.120833333333337
Debt to equity: 0.20629999999999998
Free cash flow (dilution adjusted): -95500000
Operating income: 53000000
Net income: 35600000
Long score: 4 | Short score: 9
Recommendation: Neutral
Stock screener scorecard for TRENT.NS (annual, report date 2026-03-31)
Altman Z-score: 23.009615591449997 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 31.845175527278137%
Earnings yield: 0.016168013063333306%
Return on net tangible assets: 19.601547934898246%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 27.921278201932704%
Free cash flow margin: 4.558010005989892%
Revenue growth: 6.643255238523752%
Rule of 40 score: 11.201265244513642
Market cap: 1541307891712 (Mega Cap (>= $200B))
P/E ratio: 0.7151041551568327
Debt to equity: 0.3603
Free cash flow (dilution adjusted): 95884908.85968632
Operating income: 252036880.0339127
Net income: 182421576.9393811
Long score: 10 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for TRENT.NS (quarterly, report date 2026-03-31)
Altman Z-score: 21.231681775080066 (Safe Zone)
Piotroski F-score: 2 (Weak)
Return on capital: 7.375265630879197%
Earnings yield: 0.003744472721259325%
Return on net tangible assets: 11.492936346343884%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 6.466500500728492%
Revenue growth: -10.507814625032811%
Rule of 40 score: -10.507814625032811
Market cap: 1541307891712 (Mega Cap (>= $200B))
P/E ratio: 0.7151041551568327
Debt to equity: 0.3603
Operating income: 58371131.83552353
Net income: 43779143.70495973
Long score: 5 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for TTKHLTCARE.NS (annual, report date 2026-03-31)
Altman Z-score: 6.797499385917091 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 1.6315435621900953%
Earnings yield: 0.03307433641345615%
Return on net tangible assets: 6.355202455863136%
Capitalized R&D asset: 79215.74074157097
ROCI (R&D adjusted): 1.5466093612955967%
Rosenberg metric: -119.3820592529788
Free cash flow margin: -3.1544033659141846%
Revenue growth: -2.8974265729531283%
Rule of 40 score: -6.0518299388673125
Market cap: 14797284352 (Large Cap ($10B-$200B))
P/E ratio: 0.16611643942848975
Debt to equity: 0.0219
Free cash flow (dilution adjusted): -2856136.0746078845
Operating income: 1878179.3132683341
Net income: 6960629.50402713
Long score: 4 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for TTKHLTCARE.NS (quarterly, report date 2026-03-31)
Altman Z-score: 6.29662204512307 (Safe Zone)
Piotroski F-score: 2 (Weak)
Return on capital: 0.8184921711225673%
Earnings yield: 0.016592315428678565%
Return on net tangible assets: 2.143803330025266%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 0.7920455493005326%
Revenue growth: -0.9162672282359797%
Rule of 40 score: -0.9162672282359797
Market cap: 14797284352 (Large Cap ($10B-$200B))
P/E ratio: 0.16611643942848975
Debt to equity: 0.0219
Operating income: 942221.2802034761
Net income: 2306284.442560407
Long score: 4 | Short score: 4
Recommendation: Neutral
Stock screener scorecard for VFF (quarterly, report date 2026-03-31)
Altman Z-score: 1.5025250382620197 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 1.7873278315007672%
Earnings yield: 2.2885125815198673%
Return on net tangible assets: -0.880815599257429%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 1.4097930868710922%
Free cash flow margin: -52.48218480035033%
Revenue growth: 1.251587157627426%
Rule of 40 score: -51.230597642722906
Market cap: 235095472 (Micro Cap ($50M-$300M))
P/E ratio: 12.909090909090908
Debt to equity: 0.1332
Free cash flow (dilution adjusted): -26366000
Operating income: 5044000
Net income: 2917000
Long score: 3 | Short score: 6
Recommendation: Neutral
Stock screener scorecard for ANET (annual, report date 2025-12-31)
Altman Z-score: 16.462586071583043 (Safe Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 34.387707783405865%
Earnings yield: 1.8652339717793782%
Return on net tangible assets: 28.980960985076624%
Capitalized R&D asset: 2187206000
ROCI (R&D adjusted): 24.99348168160847%
Rosenberg metric: 1.2816293769439149
Free cash flow margin: 42.3420722431349%
Revenue growth: 28.595907526666764%
Rule of 40 score: 70.93797976980167
Market cap: 164988971461.14 (Large Cap ($10B-$200B))
P/E ratio: 46.986663855197364
Debt to equity: 0
Free cash flow (dilution adjusted): 3813200000
Operating income: 3856100000
Net income: 3511400000
Long score: 14 | Short score: 2
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for CIS.DE (annual, report date 2025-07-31)
Altman Z-score: 2.913171524180607 (Grey Zone)
Piotroski F-score: 9 (Strong)
Return on capital: 315.2004033274515%
Earnings yield: 3.063657662576457%
Return on net tangible assets: -56.2977454816471%
Capitalized R&D asset: 17140440000
ROCI (R&D adjusted): 12.959980622309027%
Rosenberg metric: 0.24577226606538896
Free cash flow margin: 17.027923888869275%
Revenue growth: 5.298961024478189%
Rule of 40 score: 22.326884913347463
Market cap: 265661757190.34482 (Mega Cap (>= $200B))
P/E ratio: 26.096439802587902
Debt to equity: 0.599726746792477
Free cash flow (dilution adjusted): 9647000000
Operating income: 12504000000
Net income: 10180000000
Long score: 9 | Short score: 4
Recommendation: Neutral
Stock screener scorecard for GMED (annual, report date 2025-12-31)
Altman Z-score: 9.760267586670468 (Safe Zone)
Piotroski F-score: 9 (Strong)
Return on capital: 23.818520407032167%
Earnings yield: 5.443107871440079%
Return on net tangible assets: 27.162116254163443%
Capitalized R&D asset: 297884480
ROCI (R&D adjusted): 10.572680905599297%
Rosenberg metric: 3.0365853658536586
Free cash flow margin: 18.00801039561664%
Revenue growth: 16.654103927394114%
Rule of 40 score: 34.662114323010755
Market cap: 9893491526.99 (Mid Cap ($2B-$10B))
P/E ratio: 18.39390245746168
Debt to equity: 0.02594566227518723
Free cash flow (dilution adjusted): 529243000
Operating income: 537191000
Net income: 537868000
Long score: 13 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for HBSA3.SA (annual, report date 2025-12-31)
Altman Z-score: 1.3020855169491297 (Distress Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 10.72521215869323%
Earnings yield: 1.3476868557043762%
Return on net tangible assets: -4.091281517230028%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 9.213484245179071%
Free cash flow margin: 33.05753114878013%
Revenue growth: 76.44013016208837%
Rule of 40 score: 109.4976613108685
Market cap: 4911933853.313968 (Mid Cap ($2B-$10B))
Debt to equity: 1.7243512181945666
Free cash flow (dilution adjusted): 135191970.8029197
Operating income: 99687226.27737226
Net income: -25714963.503649633
Long score: 5 | Short score: 5
Recommendation: Neutral
Stock screener scorecard for OSIS (annual, report date 2025-06-30)
Altman Z-score: 3.7934090601137562 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 26.13660618996798%
Earnings yield: 5.216960106937309%
Return on net tangible assets: 44.60030336408159%
Capitalized R&D asset: 136764410
ROCI (R&D adjusted): 13.698269340087851%
Rosenberg metric: 0.869000382995021
Free cash flow margin: 1.4088535495100882%
Revenue growth: 11.33433587347718%
Rule of 40 score: 12.743189422987268
Market cap: 3706342645.4 (Mid Cap ($2B-$10B))
P/E ratio: 24.768891687216396
Debt to equity: 0.6830458718683102
Free cash flow (dilution adjusted): 24136000
Operating income: 222859000
Net income: 149637000
Long score: 10 | Short score: 1
Recommendation: Neutral
Stock screener scorecard for OXY.TO (annual, report date 2025-12-31)
Altman Z-score: 1.4735648470307203 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 5.82017200938233%
Earnings yield: 3.7233169771287677%
Return on net tangible assets: 9.643669867347505%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 4.978731373230959%
Free cash flow margin: 19.01079053396934%
Revenue growth: -0.754386472405163%
Rule of 40 score: 18.25640406156418
Market cap: 56764373675.25 (Large Cap ($10B-$200B))
P/E ratio: 23.961322783980584
Debt to equity: 0.6380403300726815
Free cash flow (dilution adjusted): 2996350364.9635034
Operating income: 2716788321.167883
Net income: 1729197080.2919707
Long score: 3 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for PRS.OL (annual, report date 2025-12-31)
Altman Z-score: 2.823469819363165 (Grey Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 1.6136468418626098%
Earnings yield: 0.039939296913517566%
Return on net tangible assets: 89.47740112994349%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 1.6136468418626098%
Free cash flow margin: -10.053191489361701%
Revenue growth: 51.60534950426694%
Rule of 40 score: 41.55215801490524
Market cap: 1323334122.8710163 (Small Cap ($300M-$2B))
P/E ratio: 9.286555248217658
Debt to equity: 2.091101694915254
Free cash flow (dilution adjusted): -1880597.014925373
Operating income: 696517.4129353233
Net income: 14179104.477611938
Long score: 5 | Short score: 5
Recommendation: Neutral
Stock screener scorecard for RH (annual, report date 2026-01-31)
Altman Z-score: 1.3805647945386785 (Distress Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 11.780452384848958%
Earnings yield: 5.331555068236151%
Return on net tangible assets: -43.04474470064131%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 9.916970201049704%
Free cash flow margin: 5.97214275413893%
Revenue growth: 8.135903668093688%
Rule of 40 score: 14.108046422232619
Market cap: 3763100521.4300003 (Mid Cap ($2B-$10B))
P/E ratio: 30.156190319744848
Debt to equity: 65.50029702970296
Free cash flow (dilution adjusted): 205414000
Operating income: 387268000
Net income: 124787000
Long score: 6 | Short score: 6
Recommendation: Neutral
Stock screener scorecard for SWKS (annual, report date 2025-09-30)
Altman Z-score: 5.1161004816494025 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 16.690015282730513%
Earnings yield: 5.9407891980642304%
Return on net tangible assets: 25.806451612903224%
Capitalized R&D asset: 1408983000
ROCI (R&D adjusted): 7.935156224195175%
Rosenberg metric: -0.06126325787557385
Free cash flow margin: 20.639115221806257%
Revenue growth: -2.1804691239827667%
Rule of 40 score: 18.45864609782349
Market cap: 11214268601.28 (Large Cap ($10B-$200B))
P/E ratio: 23.50506938017187
Debt to equity: 0.20897674176234562
Free cash flow (dilution adjusted): 843500000
Operating income: 524200000
Net income: 477100000
Long score: 10 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for VFF (annual, report date 2025-12-31)
Altman Z-score: 2.9834042929042366 (Grey Zone)
Piotroski F-score: 9 (Strong)
Return on capital: 9.589012320177574%
Earnings yield: 12.426659614442434%
Return on net tangible assets: 13.196570728720147%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 7.513922800471866%
Free cash flow margin: 13.600726137716093%
Revenue growth: 10.224239052203341%
Rule of 40 score: 23.824965189919432
Market cap: 444610624.5 (Small Cap ($300M-$2B))
P/E ratio: 13.705207129866526
Debt to equity: 0.12483632305796905
Free cash flow (dilution adjusted): 29369000
Operating income: 27389000
Net income: 32441000
Long score: 10 | Short score: 1
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for ZAL.DE (annual, report date 2025-12-31)
Altman Z-score: 2.3434914350039895 (Grey Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 15.268469604983052%
Earnings yield: 6.312881370927149%
Return on net tangible assets: 44.676480657309135%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 9.010329424902288%
Free cash flow margin: 6.576112488053004%
Revenue growth: 31.888801413211297%
Rule of 40 score: 38.4649139012643
Market cap: 6541638450.900001 (Mid Cap ($2B-$10B))
P/E ratio: 30.412080199442123
Debt to equity: 0.510156415882228
Free cash flow (dilution adjusted): 955176470.5882354
Operating income: 455647058.8235294
Net income: 253058823.52941176
Long score: 10 | Short score: 1
Recommendation: Neutral
Stock screener scorecard for AMAT.TO (annual, report date 2025-10-31)
Piotroski F-score: 6 (Neutral)
Return on capital: 47.052941503249826%
Earnings yield: 1.4508634643840361%
Return on net tangible assets: 31.38575415604903%
Capitalized R&D asset: 4850135126.681264
ROCI (R&D adjusted): 24.83769689708553%
Rosenberg metric: 0.2512748000530242
Free cash flow margin: 17.7312464749013%
Revenue growth: 3.640607258505409%
Rule of 40 score: 21.37185373340671
Market cap:  (Unknown)
Debt to equity: 0.3453343130051433
Free cash flow (dilution adjusted): 3592857142.8571434
Operating income: 6050000000
Net income: 4998571428.571429
Long score: 9 | Short score: 0
Recommendation: Long
Stock screener scorecard for 1717.T (annual, report date 2026-03-31)
Altman Z-score: 5.479857521420363 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 22.63307200054204%
Earnings yield: 0.08460212003630552%
Return on net tangible assets: 16.129098469662914%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 18.034765257929138%
Free cash flow margin: 20.699280960037%
Revenue growth: 0.1200273106534282%
Rule of 40 score: 20.819308270690428
Market cap: 11017861120 (Large Cap ($10B-$200B))
P/E ratio: 0.07836087095159676
Debt to equity: 0
Free cash flow (dilution adjusted): 7918512.262262262
Operating income: 7941441.441441441
Net income: 5866385.135135135
Long score: 10 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for 2307.T (annual, report date 2026-03-31)
Altman Z-score: 5.607149132164546 (Safe Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 36.266415530582%
Earnings yield: 0.1129656797614606%
Return on net tangible assets: 25.034934220725276%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 27.07233340143882%
Free cash flow margin: 12.993704807447964%
Revenue growth: 0.07971731704041105%
Rule of 40 score: 13.073422124488374
Market cap: 13758166016 (Large Cap ($10B-$200B))
P/E ratio: 0.054603848729671015
Debt to equity: 0.10529999999999999
Free cash flow (dilution adjusted): 14075538.038038038
Operating income: 12600287.787787788
Net income: 9454172.922922922
Long score: 14 | Short score: 1
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for 3434.T (annual, report date 2026-03-31)
Altman Z-score: 1.7269195065312601 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 2.3231460302587705%
Earnings yield: 0.02265129999635392%
Return on net tangible assets: 1.3544331961286042%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 1.8400488933513772%
Free cash flow margin: -1.43193166343416%
Revenue growth: -7.427863750897036%
Rule of 40 score: -8.859795414331197
Market cap: 11754537984 (Large Cap ($10B-$200B))
P/E ratio: 0.054022414216926204
Debt to equity: 0.5254
Free cash flow (dilution adjusted): -6512762.762762763
Operating income: 5274024.024024024
Net income: 8652402.402402403
Long score: 2 | Short score: 6
Recommendation: Neutral
Stock screener scorecard for 3679.T (annual, report date 2026-03-31)
Altman Z-score: 3.4737865595960367 (Safe Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 103.50078767722735%
Earnings yield: 0.11463041067413211%
Return on net tangible assets: 77.44038748137108%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 23.509064885496187%
Revenue growth: 7.475993183753488%
Rule of 40 score: 7.475993183753488
Market cap: 40262754304 (Large Cap ($10B-$200B))
P/E ratio: 0.06142123880962096
Debt to equity: 0.2132
Operating income: 36993243.24324324
Net income: 26007257.257257257
Long score: 9 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for 3800.T (annual, report date 2026-03-31)
Altman Z-score: 4.79011676329157 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 11.197281580782837%
Earnings yield: 0.12251714665649381%
Return on net tangible assets: 9.142234920391514%
Capitalized R&D asset: 5255874.606972759
ROCI (R&D adjusted): 7.135555385183645%
Rosenberg metric: -0.6040036483657657
Free cash flow margin: 6.33944966244692%
Revenue growth: -1.1471476974047414%
Rule of 40 score: 5.192301965042178
Market cap: 14915787776 (Large Cap ($10B-$200B))
P/E ratio: 0.11907547254590957
Debt to equity: 0
Free cash flow (dilution adjusted): 4895070.07007007
Operating income: 6020232.732732733
Net income: 4814414.414414414
Long score: 8 | Short score: 3
Recommendation: Neutral
Stock screener scorecard for 4337.T (annual, report date 2026-03-31)
Altman Z-score: 0.8973443373750912 (Distress Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 24.36917866215073%
Earnings yield: 0.8618318565079309%
Return on net tangible assets: 147.58085381630013%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 15.593281560411778%
Free cash flow margin: 18.933670703054403%
Revenue growth: 14.175429893982864%
Rule of 40 score: 33.10910059703727
Market cap: 42065821696 (Large Cap ($10B-$200B))
P/E ratio: 0.09561142572332808
Debt to equity: 1.4709
Free cash flow (dilution adjusted): 65540540.54054054
Operating income: 27008258.258258257
Net income: 20752002.002002
Long score: 10 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for 4373.T (annual, report date 2026-03-31)
Altman Z-score: 5.758282150110488 (Safe Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 54.34299280250217%
Earnings yield: 0.03722129381429184%
Return on net tangible assets: 86.09950114601591%
Capitalized R&D asset: 20488633.173616376
ROCI (R&D adjusted): 19.308312197460157%
Rosenberg metric: 2.9469102153000466
Free cash flow margin: 17.543710166660986%
Revenue growth: 15.900610172564425%
Rule of 40 score: 33.44432033922541
Market cap: 234378100736 (Mega Cap (>= $200B))
P/E ratio: 0.11104057747088988
Debt to equity: 0.4365
Free cash flow (dilution adjusted): 64408158.15815815
Operating income: 90221471.47147147
Net income: 65928428.42842843
Long score: 16 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for 4461.T (annual, report date 2026-03-31)
Altman Z-score: 2.8235777696694755 (Grey Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 16.006841071767912%
Earnings yield: 0.05151991363121775%
Return on net tangible assets: 13.372609619470735%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 13.398549860155617%
Free cash flow margin: 7.649060154911566%
Revenue growth: 5.912711906500725%
Rule of 40 score: 13.561772061412292
Market cap: 111416385536 (Large Cap ($10B-$200B))
P/E ratio: 0.07662197148043479
Debt to equity: 0.5003
Free cash flow (dilution adjusted): 39664664.66466466
Operating income: 63238238.23823824
Net income: 45664414.41441441
Long score: 8 | Short score: 1
Recommendation: Long
Stock screener scorecard for 7220.T (annual, report date 2026-03-31)
Altman Z-score: 2.6253126672599123 (Grey Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 12.745280560002978%
Earnings yield: 0.046968379755526715%
Return on net tangible assets: -4.774865591397851%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 11.17671707744467%
Free cash flow margin: 1.7943548387096775%
Revenue growth: -6.3928154701089825%
Rule of 40 score: -4.5984606313993055
Market cap: 198261145600 (Large Cap ($10B-$200B))
P/E ratio: 0.8473090859454495
Debt to equity: 0.7523000000000001
Free cash flow (dilution adjusted): 38976476.476476476
Operating income: 128490990.99099098
Net income: 14677177.177177178
Long score: 6 | Short score: 3
Recommendation: Neutral
Stock screener scorecard for 9101.T (annual, report date 2026-03-31)
Altman Z-score: 1.8214737924784683 (Grey Zone)
Piotroski F-score: 4 (Weak)
Return on capital: 8.543719363651608%
Earnings yield: 0.024993661779532373%
Return on net tangible assets: 6.069391516959209%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 3.202562956133753%
Free cash flow margin: 6.966900456287915%
Revenue growth: -12.360609687409815%
Rule of 40 score: -5.3937092311219
Market cap: 2399544803328 (Mega Cap (>= $200B))
P/E ratio: 0.07148307532602925
Debt to equity: 0.3822
Free cash flow (dilution adjusted): 1056406406.4064064
Operating income: 867123373.3733734
Net income: 1349305555.5555556
Long score: 5 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for BELFA (quarterly, report date 2026-03-31)
Altman Z-score: 5.49980304582553 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 7.130521829740901%
Earnings yield: 0.7542648969054105%
Return on net tangible assets: -172409.0909090909%
Capitalized R&D asset: 16352810
ROCI (R&D adjusted): 2.946208541275745%
Rosenberg metric: 0.027777777777777776
Free cash flow margin: 5.10277829134242%
Revenue growth: 1.4510793575009377%
Rule of 40 score: 6.553857648843358
Market cap: 2966299136 (Mid Cap ($2B-$10B))
P/E ratio: 43.514492753623195
Debt to equity: 0.42219999999999996
Free cash flow (dilution adjusted): 9108000
Operating income: 24361000
Net income: 14984000
Long score: 6 | Short score: 6
Recommendation: Neutral
Stock screener scorecard for BMT.DE (annual, report date 2025-12-31)
Altman Z-score: 2.055490495757568 (Grey Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 441.1275066212636%
Earnings yield: 10.61578836528884%
Return on net tangible assets: -24.407813781788352%
Capitalized R&D asset: 401062324.66643864
ROCI (R&D adjusted): 12.2419112396021%
Rosenberg metric: 9.694470332401371
Free cash flow margin: 22.014837953924246%
Revenue growth: 7.034006597156559%
Rule of 40 score: 29.048844551080805
Market cap: 116119977984 (Large Cap ($10B-$200B))
P/E ratio: 13.503460207612456
Debt to equity: 0.7284
Free cash flow (dilution adjusted): 7618918918.918919
Operating income: 15755405405.405405
Net income: 10493243243.243244
Long score: 10 | Short score: 3
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for CTRN (quarterly, report date 2026-04-30)
Altman Z-score: 2.2425492582439177 (Grey Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 2.391467891098227%
Earnings yield: 1.1249060539475597%
Return on net tangible assets: 5.607812163423566%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 2.377406418836151%
Free cash flow margin: 5.951277408623483%
Revenue growth: 0.2018290486256093%
Rule of 40 score: 6.153106457249092
Market cap: 524114016 (Small Cap ($300M-$2B))
P/E ratio: 34.06293706293707
Debt to equity: 1.8067
Free cash flow (dilution adjusted): 13739000
Operating income: 7375000
Net income: 7754000
Long score: 5 | Short score: 1
Recommendation: Neutral
Stock screener scorecard for EUREKAFORB.NS (annual, report date 2026-03-31)
Altman Z-score: 2.885764024294296 (Grey Zone)
Piotroski F-score: 7 (Neutral)
Return on capital: 56.805066762521484%
Earnings yield: 0.03241654597575195%
Return on net tangible assets: -25.53703176680481%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 4.3149910021773366%
Free cash flow margin: 5.173456016906815%
Revenue growth: 0.7766472255385977%
Rule of 40 score: 5.950103242445413
Market cap: 83623968768 (Large Cap ($10B-$200B))
P/E ratio: 0.5570770224925778
Debt to equity: 0.0063
Free cash flow (dilution adjusted): 14852914.370495973
Operating income: 25841627.80839339
Net income: 17235322.170411192
Long score: 9 | Short score: 3
Recommendation: Long
Stock screener scorecard for EUREKAFORB.NS (quarterly, report date 2026-03-31)
Altman Z-score: 2.497677736263275 (Grey Zone)
Piotroski F-score: 2 (Weak)
Return on capital: 15.264048410719559%
Earnings yield: 0.008710626626860252%
Return on net tangible assets: -12.530817634016813%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 1.1594781117748758%
Revenue growth: 0.7844219967731082%
Rule of 40 score: 0.7844219967731082
Market cap: 83623968768 (Large Cap ($10B-$200B))
P/E ratio: 0.5570770224925778
Debt to equity: 0.0063
Operating income: 6943885.120813904
Net income: 5408488.7664264515
Long score: 4 | Short score: 5
Recommendation: Neutral
Stock screener scorecard for HESTERBIO.NS (quarterly, report date 2026-03-31)
Altman Z-score: 4.8733750240504525 (Safe Zone)
Piotroski F-score: 3 (Weak)
Return on capital: 6.050528234237074%
Earnings yield: 0.013629103899477843%
Return on net tangible assets: 6.407750925072679%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 5.408182878718388%
Revenue growth: 23.025640916125184%
Rule of 40 score: 23.025640916125184
Market cap: 20139151360 (Large Cap ($10B-$200B))
P/E ratio: 0.20243422284512655
Debt to equity: 0.5296
Operating income: 3011657.4819838917
Net income: 1753497.2445951675
Long score: 3 | Short score: 2
Recommendation: Neutral
Stock screener scorecard for HESTERBIO.NS (annual, report date 2026-03-31)
Altman Z-score: 5.453403964621977 (Safe Zone)
Piotroski F-score: 8 (Strong)
Return on capital: 16.421037391574657%
Earnings yield: 0.0369891712066693%
Return on net tangible assets: 21.67622884172627%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 14.677722313464505%
Free cash flow margin: 13.924575840576791%
Revenue growth: -3.083114400999751%
Rule of 40 score: 10.84146143957704
Market cap: 20139151360 (Large Cap ($10B-$200B))
P/E ratio: 0.20243422284512655
Debt to equity: 0.5296
Free cash flow (dilution adjusted): 4908117.846545146
Operating income: 8173590.504451038
Net income: 6091988.130563798
Long score: 10 | Short score: 0
Recommendation: Strong Long (L/S Compounder)
Stock screener scorecard for HHFA.DE (quarterly, report date 2026-03-31)
Altman Z-score: 0.7434149902073545 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Return on capital: 1.306757386210978%
Earnings yield: 1.0307490511344242%
Return on net tangible assets: -6.147415226598316%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 1.0277999755309792%
Free cash flow margin: -11.927254502796368%
Revenue growth: 3.7136340022079386%
Rule of 40 score: -8.21362050058843
Market cap: 1624739968 (Small Cap ($300M-$2B))
P/E ratio: 629.3103448275862
Debt to equity: 1.8931
Free cash flow (dilution adjusted): -61821839.08045977
Operating income: 35051724.137931034
Net income: 6642528.735632184
Long score: 1 | Short score: 7
Recommendation: Neutral
Stock screener scorecard for INDOCO.NS (quarterly, report date 2026-03-31)
Altman Z-score: 1.0732787987177521 (Distress Zone)
Piotroski F-score: 1 (Weak)
Return on capital: 1.4080130825838102%
Earnings yield: 0.005888294755928103%
Capitalized R&D asset: 4060144.0971051073
ROCI (R&D adjusted): 0.9442877803289264%
Rosenberg metric: -0.7835799842984875
Revenue growth: -0.1419552565300049%
Rule of 40 score: -0.1419552565300049
Market cap: 22436923392 (Large Cap ($10B-$200B))
Debt to equity: 1.1691
Operating income: 1824925.8160237388
Net income: -2293344.6375582875
Long score: 0 | Short score: 5
Recommendation: Neutral
Stock screener scorecard for INDOCO.NS (annual, report date 2026-03-31)
Altman Z-score: 1.5864798923177243 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Return on capital: 1.2551103843008995%
Earnings yield: 0.005248857404384227%
Return on net tangible assets: -1.7552651181688916%
Capitalized R&D asset: 18227791.701735485
ROCI (R&D adjusted): 0.22078091666694843%
Rosenberg metric: -0.11658898544116203
Free cash flow margin: 5.59974120717927%
Revenue growth: -0.9711475230464361%
Rule of 40 score: 4.628593684132834
Market cap: 22436923392 (Large Cap ($10B-$200B))
Debt to equity: 1.1691
Free cash flow (dilution adjusted): 10640101.738024587
Operating income: 1626748.6222975838
Net income: -10083721.91606613
Long score: 2 | Short score: 5
Recommendation: Neutral
Stock screener scorecard for JIN.AX (annual, report date 2025-06-30)
Altman Z-score: 6.88262749638201 (Safe Zone)
Piotroski F-score: 3 (Weak)
Return on capital: 81.32012702253138%
Earnings yield: 7.041136397986667%
Return on net tangible assets: 100.4156701970163%
Capitalized R&D asset: 0
ROCI (R&D adjusted): 37.66766829869648%
Free cash flow margin: 28.623737026126694%
Revenue growth: -10.60091552656561%
Rule of 40 score: 18.022821499561083
Market cap: 433324512 (Small Cap ($300M-$2B))
P/E ratio: 10.28322440087146
Debt to equity: 0.9886
Free cash flow (dilution adjusted): 27181699.346405227
Operating income: 35148366.013071895
Net income: 26258169.934640523
Long score: 10 | Short score: 2
Recommendation: Strong Long (L/S Compounder)